Net loss was $23.0 million for the first quarter of 2025, resulting in a basic and diluted net loss per share of $0.89. Net loss was $13.3 million for the first quarter of 2024, resulting in basic and ...

Good day, and thank you for standing by. Welcome to Madrigal Pharmaceuticals' First Quarter 2025 Earnings Conference Call. At this time, all participants are in listen-only mode. After the speakers' ...

Phase 3 clinical data shows potential predictive biomarkers for treatment response, first identified in Phase 2 ...

Calluna Pharma AS (Calluna), a clinical stage biotechnology company pioneering first-in-class antibodies to treat inflammatory and fibrotic diseases, today announcedthat the company will present three ...

Puma Biotechnology, Inc. , a biopharmaceutical company, announced that clinical data on neratinib were presented in a poster session at the American Association for Cancer Research (AACR) Annual ...

“The excellent survival responses reported in patients with different tumor types in the Phase 2 study is very exciting, and we look forward to seeing these promising data replicate in the pivotal ...

Six posters highlight continued progress across antibody-drug conjugate and T cell engager platforms Novel T cell engager ZW209 demonstrates durable activity in small cell lung cancer; IND submission ...

Detailed price information for Nurexone Biologic Inc (NRX-X) from The Globe and Mail including charting and trades.

A copy of the presentation materials can be accessed on the “ Publication ” section of the Company’s website at www.bioatla.com once the presentations have concluded.